IN8BIO, Inc. (INAB): Total Assets
$32.28M
As of 2025-12-31
$21.75M
As of 2026-06-30
-0.8%
3-year compound annual growth
+9.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $32.28M | +54.1% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $20.94M | -37.9% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $33.71M | +2.0% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $33.04M | -21.8% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $42.22M | +101.9% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $20.91M | n/a | 2022-03-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| IN8BIO, Inc. (INAB) | 2025-12-31 | $32.28M | +54.1% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $32.35M | -18.2% |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | $35.78M | -55.2% |
| CEL SCI Corp (CVM) | 2025-09-30 | $28.16M | +4.3% |
| Windtree Therapeutics Inc (WINT) | 2024-12-31 | $27.88M | -14.0% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Pluri Inc. (PLUR) | 2026-06-30 | $24.88M | -35.7% |
| Viskase Holdings, Inc. (VISK) | 2025-12-31 | $42.81M | -9.2% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $43.52M | -47.2% |
Compare INAB, INMB, JSPR, CVM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗